BICX

SEC source: 0001477932-22-005236 · form4.xml · derivative · entry 1

Granier Brady James · CIK 0001570636 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,276

Underlying: Common Stock · 6,276 shares

Expires 2027-06-30

F1 · shares: On June 30, 2022, the issuer granted the reporting person an option that was 100% vested on issuance.

SEC source: 0001477932-23-000145 · form4.xml · nonDerivative · entry 1

Emry Kent · CIK 0001589628 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 97,723

F1 · kind: These shares were issued to Mr. Emry pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Mr. Emry. As compensation for his services, Mr. Emry shall be issued, upon the last day of each fiscal quarter, provided Mr. Emry is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $2.39.

SEC source: 0001477932-22-002034 · form4.xml · nonDerivative · entry 2

Ingargiola Luisa · CIK 0001447277 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,222

F2 · kind: These shares were issued to Ms. Ingargiola pursuant to the Director Agreement referenced in footnote 1. The average closing price on the three trading days immediately preceding the date of this transaction was $3.55.

SEC source: 0001477932-22-002044 · form4.xml · derivative · entry 1

Granier Brady James · CIK 0001570636 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,224

Underlying: Common Stock · 4,224 shares

Expires 2027-03-31

F1 · shares: On March 31, 2022, the issuer granted the reporting person an option that was 100% vested on issuance.

SEC source: 0001477932-22-002042 · form4.xml · nonDerivative · entry 1

Lucido Louis C. · CIK 0001539788 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,355

F1 · kind: These shares were issued to Mr. Lucido pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Mr. Lucido. As compensation for his services, Mr. Lucido shall be issued, upon the last day of each fiscal quarter, provided Mr. Lucido is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $3.55.

SEC source: 0001477932-22-002038 · form4.xml · nonDerivative · entry 2

Emry Kent · CIK 0001589628 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 95,631

F2 · kind: These shares were issued to Mr. Emry pursuant to the Director Agreement referenced in footnote 1. The average closing price on the three trading days immediately preceding the date of this transaction was $3.55.

SEC source: 0001477932-22-002037 · form4.xml · nonDerivative · entry 1

Felix Lourdes · CIK 0001569735 · Director · CEO and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,222

F1 · kind: These shares were issued to Ms. Felix pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Felix. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $3.55.

SEC source: 0001477932-22-002052 · form4.xml · nonDerivative · entry 2

GALLIGAN JOSEPH J · CIK 0001198613 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,797

F2 · kind: These shares were issued to Mr. Galligan pursuant to the Director Agreement referenced in footnote 1. The average closing price on the three trading days immediately preceding the date of this transaction was $3.55.

SEC source: 0001477932-22-000866 · form4.xml · derivative · entry 1

Granier Brady James · CIK 0001570636 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,250

Underlying: Common Stock · 11,250 shares

Expires 2027-02-10

F1 · shares: On February 11, 2022, the issuer granted the reporting person an option that was 100% vested on issuance.

SEC source: 0001477932-22-001168 · form4.xml · nonDerivative · entry 1

Felix Lourdes · CIK 0001569735 · Director · CEO and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,814

F1 · kind: These shares were issued to Ms. Felix pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Felix. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $4.38.

SEC source: 0001477932-22-001167 · form4.xml · nonDerivative · entry 1

Lucido Louis C. · CIK 0001539788 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,947

F1 · kind: These shares were issued to Mr. Lucido pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Mr. Lucido. As compensation for his services, Mr. Lucido shall be issued, upon the last day of each fiscal quarter, provided Mr. Lucido is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $4.38.

SEC source: 0001477932-22-002034 · form4.xml · nonDerivative · entry 1

Ingargiola Luisa · CIK 0001447277 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,814

F1 · kind: These shares were issued to Ms. Ingargiola pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Ingargiola. As compensation for her services, Ms. Ingargiola shall be issued, upon the last day of each fiscal quarter, provided Ms. Ingargiola is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $4.38.

SEC source: 0001477932-22-002038 · form4.xml · nonDerivative · entry 1

Emry Kent · CIK 0001589628 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 94,223

F1 · kind: These shares were issued to Mr. Emry pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Mr. Emry. As compensation for his services, Mr. Emry shall be issued, upon the last day of each fiscal quarter, provided Mr. Emry is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $4.38.

SEC source: 0001477932-22-002052 · form4.xml · nonDerivative · entry 1

GALLIGAN JOSEPH J · CIK 0001198613 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,389

F1 · kind: These shares were issued to Mr. Galligan pursuant to a Director Agreement, dated February 16, 2021, by and between BioCorRx Inc. and Mr. Galligan. As compensation for his services, Mr. Galligan shall be issued, upon the last day of each fiscal quarter, provided Mr. Galligan is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $4.38.

SEC source: 0001477932-21-007564 · form4.xml · nonDerivative · entry 2

Lucido Louis C. · CIK 0001539788 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,806

SEC source: 0001477932-21-007564 · form4.xml · nonDerivative · entry 1

Lucido Louis C. · CIK 0001539788 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,536

F1 · kind: These shares were issued to Mr. Lucido pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Mr. Lucido. As compensation for his services, Mr. Lucido shall be issued, upon the last day of each fiscal quarter, provided Mr. Lucido is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $3.62.

SEC source: 0001477932-21-007562 · form4.xml · nonDerivative · entry 1

Felix Lourdes · CIK 0001569735 · Director · CEO and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,673

F1 · kind: These shares were issued to Ms. Felix pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Felix. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $3.62.

SEC source: 0001477932-21-007561 · form4.xml · nonDerivative · entry 1

Emry Kent · CIK 0001589628 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 93,082

F1 · kind: These shares were issued to Mr. Emry pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Mr. Emry. As compensation for his services, Mr. Emry shall be issued, upon the last day of each fiscal quarter, provided Mr. Emry is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $3.62.

SEC source: 0001477932-21-007587 · form4.xml · nonDerivative · entry 1

GALLIGAN JOSEPH J · CIK 0001198613 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,248

F1 · kind: These shares were issued to Mr. Galligan pursuant to a Director Agreement, dated February 16, 2021, by and between BioCorRx Inc. and Mr. Galligan. As compensation for his services, Mr. Galligan shall be issued, upon the last day of each fiscal quarter, provided Mr. Galligan is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $3.62.

SEC source: 0001477932-21-009297 · form4.xml · nonDerivative · entry 2

Ingargiola Luisa · CIK 0001447277 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,673

F2 · kind: These shares were issued to Ms. Ingargiola pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Ingargiola. As compensation for her services, Ms. Ingargiola shall be issued, upon the last day of each fiscal quarter, provided Ms. Ingargiola is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $3.62.

SEC source: 0001477932-21-004471 · form4.xml · nonDerivative · entry 1

Emry Kent · CIK 0001589628 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,701

F1 · kind: These shares were issued to Mr. Emry pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Mr. Emry. As compensation for his services, Mr. Emry shall be issued, upon the last day of each fiscal quarter, provided Mr. Emry is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $4.13.

SEC source: 0001477932-21-004469 · form4.xml · nonDerivative · entry 1

GALLIGAN JOSEPH J · CIK 0001198613 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,867

F1 · kind: These shares were issued to Mr. Galligan pursuant to a Director Agreement, dated February 16, 2021, by and between BioCorRx Inc. and Mr. Galligan. As compensation for his services, Mr. Galligan shall be issued, upon the last day of each fiscal quarter, provided Mr. Galligan is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $4.13.

SEC source: 0001477932-21-004470 · form4.xml · nonDerivative · entry 1

Felix Lourdes · CIK 0001569735 · Director · CEO and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,292

F1 · kind: These shares were issued to Ms. Felix pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Felix. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $4.13.

SEC source: 0001477932-21-004602 · form4.xml · nonDerivative · entry 1

Lucido Louis C. · CIK 0001539788 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,155

F1 · kind: These shares were issued to Mr. Lucido pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Mr. Lucido. As compensation for his services, Mr. Lucido shall be issued, upon the last day of each fiscal quarter, provided Mr. Lucido is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $4.13.

SEC source: 0001477932-21-009297 · form4.xml · nonDerivative · entry 1

Ingargiola Luisa · CIK 0001447277 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,292

F1 · kind: These shares were issued to Ms. Ingargiola pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Ingargiola. As compensation for her services, Ms. Ingargiola shall be issued, upon the last day of each fiscal quarter, provided Ms. Ingargiola is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $4.13.

SEC source: 0001477932-21-002005 · form4.xml · nonDerivative · entry 1

Ingargiola Luisa · CIK 0001447277 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,082

F1 · kind: These shares were issued to Ms. Ingragiola pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Ingragiola. As compensation for her services, Ms. Ingragiola shall be issued, upon the last day of each fiscal quarter, provided Ms. Ingragiola is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $2.15.

SEC source: 0001477932-21-002009 · form4.xml · nonDerivative · entry 1

Lucido Louis C. · CIK 0001539788 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,945

F1 · kind: These shares were issued to Mr. Lucido pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Mr. Lucido. As compensation for his services, Mr. Lucido shall be issued, upon the last day of each fiscal quarter, provided Mr. Lucido is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $2.16.

SEC source: 0001477932-21-002006 · form4.xml · nonDerivative · entry 1

Felix Lourdes · CIK 0001569735 · Director · CEO and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,082

F1 · kind: These shares were issued to Ms. Felix pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Felix. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $2.15.

SEC source: 0001477932-21-002002 · form4.xml · nonDerivative · entry 1

Granier Brady James · CIK 0001570636 · Director · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 94,301

F1 · kind: These shares were issued to Mr. Granier pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Mr. Granier. As compensation for his services, Mr. Granier shall be issued, upon the last day of each fiscal quarter, provided Mr. Granier is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $2.15.

SEC source: 0001477932-21-002030 · primary_doc.xml · nonDerivative · entry 1

GALLIGAN JOSEPH J · CIK 0001198613 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,657

F1 · kind: These shares were issued to Mr. Galligan pursuant to a Director Agreement, dated February 16, 2021, by and between BioCorRx Inc. and Mr. Galligan. As compensation for his services, Mr. Galligan shall be issued, upon the last day of each fiscal quarter, provided Mr. Galligan is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $2.16.

SEC source: 0001477932-21-002084 · form4.xml · nonDerivative · entry 1

Emry Kent · CIK 0001589628 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,491

F1 · kind: These shares were issued to Mr. Emry pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Mr. Emry. As compensation for his services, Mr. Emry shall be issued, upon the last day of each fiscal quarter, provided Mr. Emry is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $2.16.

SEC source: 0001477932-21-001163 · form4.xml · nonDerivative · entry 2

Lucido Louis C. · CIK 0001539788 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 562,500

F3 · kind: These shares were issued to the Louis C Lucido and Carolyn M. Lucido, or their Successors, as Trustee of the Lucido Family Trust, Dated May 23, 2017 (the "Lucido Trust") pursuant to a subscription agreement by and between BioCorRx Inc. and the Lucido Trust dated February 16, 2021, fully executed on February 23, 2021, and paid for on February 26, 2020. The Reporting Person may be deemed to have investment power over the Lucido Trust.

F3 · ownership.nature: These shares were issued to the Louis C Lucido and Carolyn M. Lucido, or their Successors, as Trustee of the Lucido Family Trust, Dated May 23, 2017 (the "Lucido Trust") pursuant to a subscription agreement by and between BioCorRx Inc. and the Lucido Trust dated February 16, 2021, fully executed on February 23, 2021, and paid for on February 26, 2020. The Reporting Person may be deemed to have investment power over the Lucido Trust.

SEC source: 0001477932-21-001163 · form4.xml · nonDerivative · entry 1

Lucido Louis C. · CIK 0001539788 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,630

F1 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in three transactions at prices ranging from $1.40 to $1.45 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2 · balance_after: Due to a clerical error in the Form 4 filed by the reporting person on January 5, 2021, the Form 4 incorrectly stated that the reporting person owned 261,926 shares directly. In fact, as of January 5, 2021, the reporting person owned 61,630 shares directly and 200,000 shares indirectly through Louis and Carolyn Lucido CRT LLC (the "LLC"). The difference of 296 shares was due to the aforesaid clerical error, which the reporting person did not discover until now. This Form 4 corrects the aforesaid errors in Table 1, Column 5. Following the reported transactions on January 22, 2021, the reporting person currently owns 63,630 shares directly.

SEC source: 0001477932-21-000044 · form4.xml · nonDerivative · entry 2

Ingargiola Luisa · CIK 0001447277 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,756

F1 · kind: These shares were issued to Ms. Ingargiola pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Ingargiola. As compensation for her services, Ms. Ingargiola shall be issued, upon the last day of each fiscal quarter, provided Ms. Ingargiola is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding September 30, 2020 was $1.90. The average closing price on the three trading days immediately preceding December 31, 2020 was $1.02.

SEC source: 0001477932-20-005861 · form4.xml · nonDerivative · entry 1

Emry Kent · CIK 0001589628 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,275

F1 · kind: These shares were issued to Mr. Emry pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Mr. Emry. As compensation for his services, Mr. Emry shall be issued, upon the last day of each fiscal quarter, provided Mr. Emry is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $1.90.

SEC source: 0001477932-20-005862 · form4.xml · nonDerivative · entry 1

Lucido Louis C. · CIK 0001539788 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 257,025

F1 · kind: These shares were issued to Mr. Lucido pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Mr. Lucido. As compensation for his services, Mr. Lucido shall be issued, upon the last day of each fiscal quarter, provided Mr. Lucido is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $1.90.

SEC source: 0001477932-20-005860 · form4.xml · nonDerivative · entry 1

Felix Lourdes · CIK 0001569735 · Director · President and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,855

F1 · kind: These shares were issued to Ms. Felix pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Felix. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $1.90.

SEC source: 0001477932-20-005859 · form4.xml · nonDerivative · entry 1

Granier Brady James · CIK 0001570636 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,074

F1 · kind: These shares were issued to Mr. Granier pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Mr. Granier. As compensation for his services, Mr. Granier shall be issued, upon the last day of each fiscal quarter, provided Mr. Granier is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $1.90.

SEC source: 0001477932-21-000044 · form4.xml · nonDerivative · entry 1

Ingargiola Luisa · CIK 0001447277 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,855

F1 · kind: These shares were issued to Ms. Ingargiola pursuant to a Director Agreement, dated March 1, 2019, by and between BioCorRx Inc. and Ms. Ingargiola. As compensation for her services, Ms. Ingargiola shall be issued, upon the last day of each fiscal quarter, provided Ms. Ingargiola is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding September 30, 2020 was $1.90. The average closing price on the three trading days immediately preceding December 31, 2020 was $1.02.